Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations

Journal of Cancer Research and Clinical Oncology

Volumn 132, Issue 7, 2006, Pages 451-457

  Anttonen, A ^a   Leppa S ^a,b   Heikkila P ^c   Grenman, R ^d   Joensuu, H ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Basic fibroblast growth factor; Head and neck cancer; Larynx cancer; Proteoglycan; Serum marker; Survival; Syndecan 1

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; PROTEOHEPARAN SULFATE; SYNDECAN 1;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL TYPE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; LUNG CANCER; MALE; MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SQUAMOUS CELL CARCINOMA; TISSUE FIXATION; TREATMENT OUTCOME;

AGED; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; LONGITUDINAL STUDIES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEOGLYCANS; SYNDECAN-1; SYNDECANS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646749562     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-006-0090-z     Document Type: Article

References (28)

1. Anttonen A, Kajanti M, Heikkilä P, Jalkanen M, Joensuu H (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 79:558-564
2. Anttonen A, Leppä S, Ruotsalainen T, Alfthan H, Mattson K, Joensuu H (2003) Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 41:171-177
3. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C (2003) High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98:474-83
4. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Ownes RB, Wilson CS (2001) Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14:1052-1058
5. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M (1999) Functions of cell surface heparan sulfate proteoglygans. Annu Rev Biochem 68:729-777
6. Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT , Jayson GC (2004) Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 10:5178-5186
7. Dore J-M, Morard F, Vita N, Wijdenes J (1998) Identification and location on syndecan-1 core protein of the epitopes of B-B2 and B-B4 monoclonal antibodies. FEBS Lett 426:67-70
8. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, Sato H (2003) Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278:40764-40770
9. Filla MS, Dam P, Rapraeger AC (1998) The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J Cell Physiol 174:310-321
10. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148:811-824
11. Harada K, Masuda S, Hirano M, Nakanuma Y (2003) Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol 34:857-863
12. Jaakkola P, Määttä A, Jalkanen M (1998) The activation and composition of FiRE (an FGF-inducible response element) differ in a cell type- and growth factor-specific manner. Oncogene 17:1279-1286
13. Joensuu H, Anttonen A, Eriksson M, Mäkitaro R, Alfthan H, Kinnula V, Leppä S (2002) Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62:5210-5217
14. Kim CW, Goldberger OA, Gallo RL, Bernfield M (1994) Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 5:797-805
15. Kumar-Singh S, Jacobs W, Dhaene K, Weyn B, Bogers J, Weyler J, van Marck E (1998) Syndecan-1 expression in malignant mesothelioma: correlation with cell differentation, WT1 expression, and clinical outcome. J Pathol 186:300-305
16. Leivonen M, Lundin J, Nordling S, von Bogulawski K, Haglung C (2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology 67:11-18
17. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P, Grenman R (1997) Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol (Stockh) 117:312-315
18. Rapraeger A, Bernfield M (1983) Heparan sulfate proteoglycans from mouse mammary epithelial cells. A putative proteoglycan associates quantitatively with lipid vessels. J Biol Chem 258:3632-3636
19. Salven P, Teerenhovi L, Joensuu H (1999) A high pretreatment serum basic fibroblast growth factor concentration is independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 94:3334-3339
20. Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjort-Hansen H, Sanderson RD, Waage A, Sundan A (2000a) High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 96:3139-3146
21. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IMS, Abildgaard N, Waage A, Borset M (2000b) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95:388-392
22. Seidel C, Ringden O, Remberger M (2003) Increased levels of syndecan-1 in serum during acute graft-versus-host disease. Transplantation 76:423-426
23. Shah L, Walter KL, Borczuk AC, Kawut SM, Sonett JR, Gorenstein L, Ginsburg ME, Steinglass KM, Powell CA (2004) Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101:1632-1638
24. Spring J, Paine-Saunders SE, Hynes RO, Bernfield M (1994) Drosophila syndecan: conservation of cell-surface heparan sulfate proteoglycan. Proc Natl Acad Sci USA 91:3334-3338
25. Volk R, Schwartz JJ, Li J, Rosenberg RD, Simons M (1999) The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction. J Biol Chem 274:24417-24424
26. Wiksten JP, Lundin J, Norling S, Kokkola A, Haglund C (2000) A prognostic value of syndecan-1 in gastric cancer. Anticancer Res 20:4905-4908
27. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100:610-617
28. Yuan K, Hong TM, Chen JJ, Tsai WH, Lin MT (2004) Syndecan-1 upregulated by ephrinB2/EphB4 plays dual roles in inflammatory angiogenesis. Blood 104:1025-1033